Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

A first-in-class dual phosphodiesterase 3 (PDE3 ... Approval was supported by the phase III ENHANCE-1 and ENHANCE-2 trials, both of which demonstrated improvements in lung function and reduced ...

This inhibition of phosphodiesterase, specifically of isoenzyme III, results in an increase in cAMP in vascular tissue and platelets. The platelet aggregation cilostazol inhibits is normally ...